Follicular B-cell Lymphoma (FL) is a malignancy of follicle center cells, characterized by a circular or nodular growth pattern with slow proliferation. After diffuse large B-cell lymphoma (DLBCL), FL is the second most frequent type of Non-Hodgkin’s Lymphoma (NHL), accounting for 22%–35...
英文名:primarycellBlymphomaofcutis 缩写:PCBLC别名: 疾病代码: ICD:C85.1 概述:原发性皮肤B细胞淋巴瘤(PCBLC)是NHL的一种类型,NHL是一种起源于淋巴瘤系统的具有异质性的恶性疾病。约25%NHL发生于结外。除胃肠道外,皮肤是第二大常见的结外侵犯部位。在过去几十年中,对于皮肤淋巴瘤的相关知识只是从皮肤T细胞淋...
Finally, we found that depletion of FcγRI+ cells inhibited the cancer cell-killing activity of XMT-2056 in cancer cell and PBMC co-cultures more substantially compared to depletion of FcγRIII+ cells or CD56+ NK cells, indicating a greater contribution of myeloid cells to the XMT-2056 mec...
To date, the limited number of cell surface antigens studied and the lack of consensual definitions of the Breg subset phenotype have impeded direct comparison of human B-cell subsets with regulatory function. In murine models, B cells with regulatory function were found within CD1dhiCD5+ (B10...
Diffuse large B cell lymphoma ICD-O-3: International Classification of Diseases for Oncology, the Third Edition NHIRD: National Health Insurance Research Database NHL: Non-Hodgkin lymphoma OS: Overall survival R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone R-CVP: ...
Furthermore, recent studies have found that CHB is associated with the development of non-Hodgkin lymphoma (NHL), diffuse large B-cell lymph- oma (DLBCL), follicular lymphoma (FL) and T-cell lymph- omas (TCL) [36,37]. During the pathogenic process of CHB and CHC, many patients develop...
219例弥漫性大B细胞淋巴瘤免疫表型及遗传学特征分析
营业期限44258-10-20至74255-04-24经营状态存续 公司类型有限责任公司(自然人投资或控股)成立日期2012-04-16 法人代表吴仕海注册机构厦门市海沧区工商行政管理局 经营范围原油加工及石油制品制造(不含危险化学品和监控化学品及非药品类易制毒化学品);汽车零部件及配件制造;电子工业专用设备制造;其他计算机制造;汽车零...
CPOP, a potentially less cardiotoxic option, was given to patients with aggressive B-cell NHL who had relapsed after CHOP or CHOP-R therapy, and was found to be highly active and adequately tolerated in patients with up to 450 mg/m2 of prior doxorubicin [10]. This phase II, comparative ...
Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60...